Assembly Biosciences raises $115M gross in underwritten equity offering; underwriters exercise option in full

ASSEMBLY BIOSCIENCES, INC.

Closed offering of 3,924,624 common shares at $26.50 and pre-funded warrants for 415,000 shares at $26.499.
Net proceeds of approximately $107.4M after underwriting discounts and estimated expenses.
Investors include Gilead Sciences, Commodore Capital, Farallon Capital, and others.
Proceeds to fund clinical development of pipeline candidates and for general corporate purposes.
Underwriters' 30-day option for 566,040 additional shares exercised in full on May 22.

item 1.01 item 8.01 item 9.01

Machine-readable event card

schema_version: secwatch.filing_event.v1
accession: 0001193125-26-239277
form_type: 8-K
ticker: ASMB
cik: 0001426800
company_name: ASSEMBLY BIOSCIENCES, INC.
filed_at: 2026-05-26T20:10:16+00:00
discovered_at: 2026-05-26T20:11:00.385817+00:00
generated_at: 2026-05-26T20:14:11.107921+00:00
sec_items: ["1.01", "8.01", "9.01"]
event_type: other_material
sentiment: positive
materiality_score: 0.75
confidence: high
secwatch_canonical_url: https://secwatch.observer/filing/0001193125-26-239277
json_url: https://secwatch.observer/filing/0001193125-26-239277.json
markdown_url: https://secwatch.observer/filing/0001193125-26-239277.md
text_url: https://secwatch.observer/filing/0001193125-26-239277.txt
edgar_index_url: https://www.sec.gov/Archives/edgar/data/1426800/000119312526239277/0001193125-26-239277-index.htm
edgar_primary_document_url: https://www.sec.gov/Archives/edgar/data/1426800/000119312526239277/asmb-20260521.htm
generated_by_model: deepseek-v4-flash:cloud@v2
review_status: machine_generated
human_reviewed: false
corrected: false
correction_note: null
correction_timestamp: null
superseded_by: null

JSON Markdown Plain text

Source: SEC EDGAR

accession 0001193125-26-239277

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.